AR026255A1 - Combinaciones antivirales. - Google Patents
Combinaciones antivirales.Info
- Publication number
- AR026255A1 AR026255A1 ARP000105645A ARP000105645A AR026255A1 AR 026255 A1 AR026255 A1 AR 026255A1 AR P000105645 A ARP000105645 A AR P000105645A AR P000105645 A ARP000105645 A AR P000105645A AR 026255 A1 AR026255 A1 AR 026255A1
- Authority
- AR
- Argentina
- Prior art keywords
- hbv
- combinations
- refers
- nucleoside
- antiviral combinations
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 abstract 1
- 229960001627 lamivudine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/429,863 US6432966B2 (en) | 1999-10-29 | 1999-10-29 | Antiviral combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR026255A1 true AR026255A1 (es) | 2003-02-05 |
Family
ID=23705033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105645A AR026255A1 (es) | 1999-10-29 | 2000-10-26 | Combinaciones antivirales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6432966B2 (https=) |
| EP (1) | EP1225904B1 (https=) |
| JP (1) | JP2003512421A (https=) |
| AR (1) | AR026255A1 (https=) |
| AT (1) | ATE273012T1 (https=) |
| AU (1) | AU1042701A (https=) |
| DE (1) | DE60012961T2 (https=) |
| ES (1) | ES2225245T3 (https=) |
| TW (1) | TWI282735B (https=) |
| WO (1) | WO2001030329A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20053504B (en) * | 2000-02-29 | 2005-05-10 | Bristol Myers Squibb Co | Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| US8168568B1 (en) * | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| CN102552210B (zh) * | 2012-01-10 | 2013-12-11 | 四川海思科制药有限公司 | 一种恩替卡韦胶囊组合物及其制备方法 |
| KR20170132327A (ko) * | 2015-04-07 | 2017-12-01 | 스프링 뱅크 파마슈티칼스, 인크. | Hbv 감염의 치료를 위한 조성물 및 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800452D0 (sv) * | 1998-02-13 | 1998-02-13 | Medivir Ab | Antivirals |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| US5206244A (en) | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| WO1992020344A1 (en) | 1991-05-16 | 1992-11-26 | Glaxo Group Limited | Antiviral combinations containing nucleoside analogs |
| IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| WO1998046241A1 (en) * | 1997-04-15 | 1998-10-22 | Advanced Viral Research Corp. | A combination therapy for hiv infections |
| CA2309357A1 (en) * | 1997-09-25 | 1999-04-01 | Bud C. Tennant | Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection |
-
1999
- 1999-10-29 US US09/429,863 patent/US6432966B2/en not_active Expired - Lifetime
-
2000
- 2000-10-26 AR ARP000105645A patent/AR026255A1/es not_active Application Discontinuation
- 2000-10-27 JP JP2001532749A patent/JP2003512421A/ja active Pending
- 2000-10-27 AU AU10427/01A patent/AU1042701A/en not_active Abandoned
- 2000-10-27 AT AT00971593T patent/ATE273012T1/de not_active IP Right Cessation
- 2000-10-27 DE DE60012961T patent/DE60012961T2/de not_active Expired - Lifetime
- 2000-10-27 EP EP00971593A patent/EP1225904B1/en not_active Expired - Lifetime
- 2000-10-27 ES ES00971593T patent/ES2225245T3/es not_active Expired - Lifetime
- 2000-10-27 TW TW089122670A patent/TWI282735B/zh not_active IP Right Cessation
- 2000-10-27 WO PCT/GB2000/004137 patent/WO2001030329A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1225904B1 (en) | 2004-08-11 |
| ES2225245T3 (es) | 2005-03-16 |
| DE60012961T2 (de) | 2005-08-18 |
| AU1042701A (en) | 2001-05-08 |
| US6432966B2 (en) | 2002-08-13 |
| ATE273012T1 (de) | 2004-08-15 |
| EP1225904A2 (en) | 2002-07-31 |
| WO2001030329A3 (en) | 2001-11-01 |
| US20020002180A1 (en) | 2002-01-03 |
| JP2003512421A (ja) | 2003-04-02 |
| TWI282735B (en) | 2007-06-21 |
| WO2001030329A2 (en) | 2001-05-03 |
| DE60012961D1 (de) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW366347B (en) | Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues | |
| Torresi et al. | Antiviral chemotherapy for the treatment of hepatitis B virus infections | |
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| RU94013464A (ru) | Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции | |
| MY109796A (en) | 1,3-oxathiolane nucleoside analogues. | |
| CY1108355T1 (el) | Συνθεσεις και μεθοδοι για συνδυασμενη αντι-ιικη θεραπεια | |
| DK1658302T3 (da) | Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C | |
| EA199700203A1 (ru) | Синергические комбинации зидовудина, 1592u89 и 3тс или ftc | |
| PA8588501A1 (es) | Derivados antivirales de nucleósidos | |
| UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
| ES2138969T3 (es) | Combinacion de nucleosidos antivirales. | |
| NO20034878D0 (no) | Antivirale forbindelser | |
| AR026255A1 (es) | Combinaciones antivirales. | |
| AR023661A1 (es) | Combinaciones antivirales | |
| AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
| WO2004043402A3 (en) | Modified nucleosides as antiviral agents | |
| AR043332A1 (es) | Composiciones y metodos para terapia antiviral | |
| AR040805A1 (es) | Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral | |
| RU2005138167A (ru) | Противовирусное средство (варианты) и способ лечения на его основе | |
| WO2000018383A3 (en) | Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester | |
| WO2000016754A3 (en) | Antiviral combinations comprising lamivudine and lobucavir | |
| AR019532A1 (es) | COMPOSICIoN FARMACÉUTICA DEL COMPUESTO 1,5-DIDEOXI-1,5-IMIN-D-GLUCITOL N-SUSTITUIDO | |
| DE602005006397D1 (de) | Nukleosidanaloga mit antiviraler wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |